At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 100 enrolled
Drug / intervention
Dapagliflozin 10mg +1 moredrug
Likely dose
Dapagliflozin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients - DACAMI (a Randomized Controlled Clinical Trial)
In Brief
A Phase 3 clinical trial evaluating Dapagliflozin 10mg and Glucose Tab for Anterior MI. Completed, enrolled 100 participants across 2 sites.
Detailed Summary
Sodium glucose co-transporter 2 inhibitors (SGLT2i) proved their favorable outcomes in heart failure. However, it is still unknown if their role extent into preventing heart failure, especially after acute myocardial infarction. This study aimed at identifying if there is such role for SGLT2i.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnterior MI
CountriesEgypt
CollaboratorsAin Shams University
Timeline
Phase 3CompletedFinished
20222023202420252026
Enrollment StartOct 2021
Primary CompletionApr 2022
First PostedJun 2022
TodayJul 2026
First PostedJun 21, 2022
Enrollment StartOct 1, 2021
Primary CompletionApr 30, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.0 years ago
Interventions
Dapagliflozin 10mgdrug
10mg Tab once daily
Glucose Tabdrug
Placebo Oral Tablet